血浆sCD_(40)L与急性冠状动脉综合征相关性的研究

The Research in the Correlationship between Plasma Soluble sCD_(40)L and the Acute Coronary Syndrome

目的分析血浆可溶性CD40L(sCD_(40)L)在冠心病患者及正常对照组血浆中的变化,探讨阿托伐他汀干预治疗对急性冠状动脉综合征患者血浆sCD_(40)L水平的影响。方法急性冠状动脉综合征(ACS)70例,稳定型心绞痛(SAP)36例,正常对照组40例。分别测定以上各组患者入院时的血浆sCD_(40)L水平。将ACS患者给予阿托伐他汀钙20 mg/d治疗3周后测定ACS患者血浆sCD_(40)L水平。结果 1 ACS组和SAP组血浆sCD_(40)L水平均高于对照组。ACS组血浆sCD_(40)L水平高于SAP组。2阿托伐他汀治疗3周后ACS组血浆sCD_(40)L水平下降,治疗前后有统计学意义。结论血浆sCD_(40)L与冠心病的发生及斑块的不稳定有关,阿托伐他汀治疗可降低ACS患者sCD_(40)L水平。

Objective To analyse the change of plasma soluble CD40L ill diffremt patients with coronary heart disease and the normal controls, to investigate the effects of datorvastatin on serum levels of sCD4oL, in patient with acute coronary syndrome. Methods 70 cases patients with acute coronary syndrome,36 cases patients with stable angina pectoris, and 40 cases of normal controls, determined the level of sCD4oL, group ACS were given atorvastatin 20 mg/d, 3 weeks after therapy, measured the serum levels of sCD4oL. Results （1）Plasma sCD40L levels in ACS and SAP group is higher than control group, the sCD40L of the ACS group is higher than that of SAP group. （2）3 weeks after atorvastatin therapy, the levels of sCD^L of ACS group decreased significantly. Conclusions Blood plasma sCD40L is related to coronary disease＇s occurrence and and plaque instability, atorvastatin therapy can reduce the sCD40L levels in patient with ACS.